{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:51:42Z","timestamp":1791967902666,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hong Kong UGC Research Matching Grant Scheme","award":["8601722"],"award-info":[{"award-number":["8601722"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to provide a long-term comparison of patient-reported functional outcomes (PROs) across various treatments for localized PCa over five years in an Asian population. This was a prospective study involving 866 patients with PCa who were undergoing treatment, including active surveillance (AS)(\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009126), radical prostatectomy (RP) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009332), radiation therapy (RT) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009339) and focal therapy (FT)(\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200969). Patients were required to complete the EPIC-26 questionnaire at baseline and annually for 5 years, and were followed up until the most recent completion of the questionnaire, loss to follow-up, or death. Longitudinal functional outcomes were analyzed using linear mixed-effects models; the model included fixed effects for treatment modality, time, a treatment\u00d7time interaction, and clinically relevant covariates, including age, body mass index (BMI), Charlson Comorbidity Index, and AUA risk group classification. Over a median follow-up of 42.81months, RP resulted in the worst outcome in urinary continence (mean difference: \u221219, 95%CI: \u221224 to \u2212\u200914;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and sexual function mean difference: \u221222, 95%CI: \u221226 to \u2212\u200917;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) in the first year, as compared to AS. RT was associated with an early decline in bowel function and hormonal dysfunction, which was most severe at 1\u20133 years, but both functions had recovered afterwards. FT was associated with favorable functional preservation in most domains compared to RP and RT, though sexual function declined progressively from baseline. No significant differences in sexual function were observed between FT and AS beyond 1 year. Different treatment modalities (AS, RP, RT, FT) resulted in distinct functional outcomes profiles.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-62051-y","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:14:17Z","timestamp":1783944857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of different treatment modalities for localized prostate cancer on patient-reported quality of life outcomes in an Asian Cohort"],"prefix":"10.1038","volume":"16","author":[{"given":"Yan Hiu Athena","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Yee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man Chung","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi Lam","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yip Pak","family":"Hin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Fei Venus","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Ho","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Ka Wai","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"62051_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"62051_CR2","unstructured":"Cancer Online Resource Hub. Overview of Cancer Statistics in Hong Kong, < (2022). https:\/\/www.cancer.gov.hk\/en\/hong_kong_cancer\/overview_of_cancer_statistics_in_hong_kong.html"},{"key":"62051_CR3","unstructured":"Guidelines on Prostate Cancer. (2025). https:\/\/uroweb.org\/guidelines\/prostate-cancer\/summary-of-changes\/2025"},{"key":"62051_CR4","unstructured":"Cancer of the Prostate. - Cancer Stat Facts, https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html (2018)."},{"key":"62051_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy, F. C. et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl. J. Med. 388, 1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa2214122 (2023).","journal-title":"N Engl. J. Med."},{"key":"62051_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jama.2019.20675","volume":"323","author":"KE Hoffman","year":"2020","unstructured":"Hoffman, K. E. et al. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA 323, 149\u2013163. https:\/\/doi.org\/10.1001\/jama.2019.20675 (2020).","journal-title":"JAMA"},{"key":"62051_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12894-022-01117-1","volume":"22","author":"T Tiruye","year":"2022","unstructured":"Tiruye, T. et al. Patient-reported functional outcome measures and treatment choice for prostate cancer. BMC Urol. 22, 169. https:\/\/doi.org\/10.1186\/s12894-022-01117-1 (2022).","journal-title":"BMC Urol."},{"key":"62051_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/ua.ua_75_22","volume":"15","author":"K Hashine","year":"2023","unstructured":"Hashine, K., Tada, K., Minato, R., Sawada, Y. & Matsumura, M. Patient-reported outcomes after robot-assisted radical prostatectomy and institutional learning curve for functional outcomes. Urol. Ann. 15, 60\u201367. https:\/\/doi.org\/10.4103\/ua.ua_75_22 (2023).","journal-title":"Urol. Ann."},{"key":"62051_CR9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jpainsymman.2017.02.010","volume":"53","author":"WWT Lam","year":"2017","unstructured":"Lam, W. W. T., Tse, M. A., Ng, C. N. L., Chung, E. K. M. & Fielding, R. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer. J. Pain Symptom Manage. 53, 1085\u20131090. https:\/\/doi.org\/10.1016\/j.jpainsymman.2017.02.010 (2017).","journal-title":"J. Pain Symptom Manage."},{"key":"62051_CR10","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.4103\/jpbs.jpbs_1742_24","volume":"17","author":"R Agrawal","year":"2025","unstructured":"Agrawal, R., Sabale, V. P. & Ahmad, S. A. U. A. Guidelines for Screening of Prostate Cancer 2023. J. Pharm. Bioallied Sci. 17, 1976\u2013S1977. https:\/\/doi.org\/10.4103\/jpbs.jpbs_1742_24 (2025).","journal-title":"J. Pharm. Bioallied Sci."},{"key":"62051_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.eururo.2014.08.075","volume":"67","author":"NE Martin","year":"2015","unstructured":"Martin, N. E. et al. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur. Urol. 67, 460\u2013467. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.075 (2015).","journal-title":"Eur. Urol."},{"key":"62051_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12885-023-10732-6","volume":"23","author":"NB Bulamu","year":"2023","unstructured":"Bulamu, N. B., Mpundu-Kaambwa, C., O\u2019Callaghan, M. & Kaambwa, B. Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer. BMC Cancer. 23, 297. https:\/\/doi.org\/10.1186\/s12885-023-10732-6 (2023).","journal-title":"BMC Cancer"},{"key":"62051_CR13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","volume":"76","author":"KM Szymanski","year":"2010","unstructured":"Szymanski, K. M., Wei, J. T., Dunn, R. L. & Sanda, M. G. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 76, 1245\u20131250. https:\/\/doi.org\/10.1016\/j.urology.2010.01.027 (2010).","journal-title":"Urology"},{"key":"62051_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamainternmed.2024.5994","volume":"185","author":"TJ Daskivich","year":"2025","unstructured":"Daskivich, T. J., Luu, M., Heard, J., Thomas, I. C. & Leppert, J. T. Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era. JAMA Intern. Med. 185, 28\u201336. https:\/\/doi.org\/10.1001\/jamainternmed.2024.5994 (2025).","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"62051_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","volume":"85","author":"TA Skolarus","year":"2015","unstructured":"Skolarus, T. A. et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology 85 (1), 101\u2013105. https:\/\/doi.org\/10.1016\/j.urology.2014.08.044 (2015).","journal-title":"Urology"},{"key":"62051_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.euf.2024.09.002","volume":"11","author":"A Cormio","year":"2025","unstructured":"Cormio, A. et al. Stapled W-shaped (Hautmann) Orthotopic Ileal Neobladder. Functional Results and Complications over a 13-year Period. Eur. Urol. Focus. 11, 165\u2013171. https:\/\/doi.org\/10.1016\/j.euf.2024.09.002 (2025).","journal-title":"Eur. Urol. Focus"},{"key":"62051_CR17","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(16)30592-X","volume":"388","author":"JW Yaxley","year":"2016","unstructured":"Yaxley, J. W. et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 388, 1057\u20131066. https:\/\/doi.org\/10.1016\/S0140-6736(16)30592-X (2016).","journal-title":"Lancet"},{"key":"62051_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.eururo.2012.05.044","volume":"62","author":"G Novara","year":"2012","unstructured":"Novara, G. et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur. Urol. 62, 431\u2013452. https:\/\/doi.org\/10.1016\/j.eururo.2012.05.044 (2012).","journal-title":"Eur. Urol."},{"key":"62051_CR19","doi-asserted-by":"publisher","unstructured":"d\u2019Altilia, N. et al. A Matched-Pair Analysis after Robotic and Retropubic Radical Prostatectomy: A New Definition of Continence and the Impact of Different Surgical Techniques. Cancers (Basel). 14. https:\/\/doi.org\/10.3390\/cancers14184350 (2022).","DOI":"10.3390\/cancers14184350"},{"key":"62051_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3122\/jabfm.2012.06.120128","volume":"25","author":"J Xu","year":"2012","unstructured":"Xu, J., Neale, A. V., Dailey, R. K., Eggly, S. & Schwartz, K. L. Patient perspective on watchful waiting\/active surveillance for localized prostate cancer. J. Am. Board. Fam Med. 25, 763\u2013770. https:\/\/doi.org\/10.3122\/jabfm.2012.06.120128 (2012).","journal-title":"J. Am. Board. Fam Med."},{"key":"62051_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/s0027-9684(15)30359-x","volume":"103","author":"J Xu","year":"2011","unstructured":"Xu, J., Dailey, R. K., Eggly, S., Neale, A. V. & Schwartz, K. L. Men\u2019s perspectives on selecting their prostate cancer treatment. J. Natl. Med. Assoc. 103, 468\u2013478. https:\/\/doi.org\/10.1016\/s0027-9684(15)30359-x (2011).","journal-title":"J. Natl. Med. Assoc."},{"key":"62051_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.23736\/S2724-6051.25.06772-2","volume":"77","author":"F Zattoni","year":"2025","unstructured":"Zattoni, F. et al. SYNERGY in uro-oncology: navigating decisions in low-risk prostate cancer. Minerva Urol. Nephrol. 77, 752\u2013754. https:\/\/doi.org\/10.23736\/S2724-6051.25.06772-2 (2025).","journal-title":"Minerva Urol. Nephrol."},{"key":"62051_CR23","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/diagnostics16091310","volume":"16","author":"F Zattoni","year":"2026","unstructured":"Zattoni, F. et al. Beyond One-Size-Fits-All Active Surveillance for Low-Risk Prostate Cancer: Risk-Adapted Follow-Up, De-Escalation Pathways, and Focal Therapy as Tailored Strategy. Diagnostics 16, 1310. https:\/\/doi.org\/10.3390\/diagnostics16091310 (2026).","journal-title":"Diagnostics"},{"key":"62051_CR24","doi-asserted-by":"publisher","first-page":"11322","DOI":"10.4081\/aiua.2023.11322","volume":"95","author":"P Pepe","year":"2023","unstructured":"Pepe, P. et al. 68Ga-PSMA PET\/CT evaluation in men enrolled in prostate cancer Active Surveillance. Arch. Ital. Urol. Androl. 95, 11322. https:\/\/doi.org\/10.4081\/aiua.2023.11322 (2023).","journal-title":"Arch. Ital. Urol. Androl."},{"key":"62051_CR25","doi-asserted-by":"publisher","first-page":"13635","DOI":"10.4081\/aiua.2025.13635","volume":"97","author":"S Vatrano","year":"2025","unstructured":"Vatrano, S. et al. BRCA mutations and prostate cancer: should urologist improve daily clinical practice? Arch. Ital. Urol. Androl. 97, 13635. https:\/\/doi.org\/10.4081\/aiua.2025.13635 (2025).","journal-title":"Arch. Ital. Urol. Androl."},{"key":"62051_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/clinpract14020039","volume":"14","author":"E Bologna","year":"2024","unstructured":"Bologna, E. et al. Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX. Clin. Pract. 14, 508\u2013520. https:\/\/doi.org\/10.3390\/clinpract14020039 (2024).","journal-title":"Clin. Pract."},{"key":"62051_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/pon.3657","volume":"24","author":"LD Venderbos","year":"2015","unstructured":"Venderbos, L. D. et al. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psychooncology 24, 348\u2013354. https:\/\/doi.org\/10.1002\/pon.3657 (2015).","journal-title":"Psychooncology"},{"key":"62051_CR28","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/JU.0000000000001091","volume":"204","author":"JS Detsky","year":"2020","unstructured":"Detsky, J. S. et al. Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer. J. Urol. 204, 934\u2013940. https:\/\/doi.org\/10.1097\/JU.0000000000001091 (2020).","journal-title":"J. Urol."},{"key":"62051_CR29","unstructured":"Hutch, F. Prostate Cancer Screening and Early Detection, <https:\/\/www.fredhutch.org\/en\/patient-care\/prevention\/prostate-cancer-early-detection.html"},{"key":"62051_CR30","unstructured":"KS, S. Prostate Cancer Awareness: Challenging Stereotypes and Empowering Support, < (2024). https:\/\/www.narayanahealth.org\/blog\/prostate-cancer-awareness-challenging-stereotypes-and-empowering-support"},{"key":"62051_CR31","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.euo.2025.05.004","volume":"8","author":"A Lantz","year":"2025","unstructured":"Lantz, A. et al. Robotic Versus Open Radical Prostatectomy, Differences in Prostate Cancer-specific Survival-12 Years of Follow-up in the LAParoscopic Prostatectomy Robot Open Trial. Eur. Urol. Oncol. 8, 1524\u20131532. https:\/\/doi.org\/10.1016\/j.euo.2025.05.004 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"62051_CR32","doi-asserted-by":"publisher","unstructured":"Lasorsa, F. et al. Focal Therapy for Prostate Cancer: Recent Advances and Insights. Curr. Oncol. 32 https:\/\/doi.org\/10.3390\/curroncol32010015 (2024).","DOI":"10.3390\/curroncol32010015"},{"key":"62051_CR33","doi-asserted-by":"publisher","first-page":"100694","DOI":"10.1016\/j.ctro.2023.100694","volume":"44","author":"V Zamora","year":"2024","unstructured":"Zamora, V. et al. Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures. Clin. Transl Radiat. Oncol. 44, 100694. https:\/\/doi.org\/10.1016\/j.ctro.2023.100694 (2024).","journal-title":"Clin. Transl Radiat. Oncol."},{"key":"62051_CR34","unstructured":"Urinary Dysfunction After. Prostate Cancer Treatment www.hopkinsmedicine.org\/health\/treatment-tests-and-therapies\/urinary-dysfunction-after-prostate-cancer-treatment (2021)."},{"key":"62051_CR35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","volume":"74","author":"S Guillaumier","year":"2018","unstructured":"Guillaumier, S. et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur. Urol. 74, 422\u2013429. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.006 (2018).","journal-title":"Eur. Urol."},{"key":"62051_CR36","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan, J. L. et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl. J. Med. 375, 1425\u20131437. https:\/\/doi.org\/10.1056\/NEJMoa1606221 (2016).","journal-title":"N Engl. J. Med."},{"key":"62051_CR37","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.juro.2015.11.072","volume":"195","author":"D Liberman","year":"2016","unstructured":"Liberman, D., Jarosek, S., Virnig, B. A., Chu, H. & Elliott, S. P. The Patient Burden of Bladder Outlet Obstruction after Prostate Cancer Treatment. J. Urol. 195, 1459\u20131463. https:\/\/doi.org\/10.1016\/j.juro.2015.11.072 (2016).","journal-title":"J. Urol."},{"key":"62051_CR38","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jama.2023.26491","volume":"331","author":"HA Al","year":"2024","unstructured":"Al, H. A. et al. Functional Outcomes After Localized Prostate Cancer Treatment. JAMA 331, 302\u2013317. https:\/\/doi.org\/10.1001\/jama.2023.26491 (2024).","journal-title":"JAMA"},{"key":"62051_CR39","doi-asserted-by":"publisher","first-page":"917941","DOI":"10.1155\/2011\/917941","volume":"2011","author":"NL Do","year":"2011","unstructured":"Do, N. L., Nagle, D. & Poylin, V. Y. Radiation proctitis: current strategies in management. Gastroenterol. Res. Pract. 2011, 917941 (2011).","journal-title":"Gastroenterol. Res. Pract."},{"issue":"1","key":"62051_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0360-3016(96)00468-3","volume":"37","author":"TE Schultheiss","year":"1997","unstructured":"Schultheiss, T. E. et al. Late GI and GU complications in the treatment of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 37 (1), 3\u201311 (1997).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"62051_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1200\/JCO.1997.15.1.223","volume":"15","author":"CJ Beard","year":"1997","unstructured":"Beard, C. J. et al. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. J. Clin. Oncol. 15 (1), 223\u2013229 (1997).","journal-title":"J. Clin. Oncol."},{"key":"62051_CR42","unstructured":"McKeown, D. G., Gasalberti, D. P., Goldstein, S. & Radiation, P. Jan 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan\u2013. (2024)."},{"key":"62051_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4081\/aiua.2022.2.166","volume":"94","author":"P Pepe","year":"2022","unstructured":"Pepe, P. et al. Erectile dysfunction following hydrogel injection and hypofractionated radiotherapy for prostate cancer: Our experience in 56 cases. Arch. Ital. Urol. Androl. 94, 166\u2013168. https:\/\/doi.org\/10.4081\/aiua.2022.2.166 (2022).","journal-title":"Arch. Ital. Urol. Androl."},{"key":"62051_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0090-4295(02)01579-0","volume":"60","author":"MR Smith","year":"2002","unstructured":"Smith, M. R. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 60, 79\u201385 (2002). discussion 86.","journal-title":"Urology"},{"key":"62051_CR45","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/bonekey.2015.85","volume":"4","author":"M Bienz","year":"2015","unstructured":"Bienz, M. & Saad, F. Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review. Bonekey Rep. 4, 716. https:\/\/doi.org\/10.1038\/bonekey.2015.85 (2015).","journal-title":"Bonekey Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62051-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62051-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62051-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:23:52Z","timestamp":1791966232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62051-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["62051"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-62051-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8946893\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32122"}}